or Try an Advanced Search...

    Biotie Therapies Stocks List

    Symbol Grade Name % Change
    VTVT D vTv Therapeutics Inc. -4.38
    CANF F Can-Fite Biopharma Ltd Sponsored ADR (Israel) -0.51
    LXRX F Lexicon Pharmaceuticals, Inc. 11.88
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Diabetes Glaucoma Inflammatory Diseases Medicine Psoriasis Rheumatoid Arthritis Alzheimer's Disease Arthritis Autoimmune Disease Biotechnology Buparlisib Cancer Carcinoma Chronic Obstructive Pulmonary Disease Clinical Development Clinical Trial Colitis Disease Drug Discovery

    Related ETFs - A few ETFs which own one or more of the above listed Biotie Therapies stocks.

    Symbol Grade Name Weight
    BBP C BioShares Biotechnology Products Fund 0.74
    QQQS B Invesco NASDAQ Future Gen 200 ETF 0.27
    IBBQ F Invesco Nasdaq Biotechnology ETF 0.04
    IWC B iShares Microcap ETF 0.04
    TXSS A Texas Small Cap Equity Index ETF 0.04
    View all Biotie Therapies ETFs...
    Compare ETFs
    Compare BBP to QQQS Compare QQQS to IBBQ Compare QQQS to IWC

        Biotie Therapies Stocks Recent News

        Date Stock Title
        Nov 22 LXRX Lexicon Pharmaceuticals to Cut 60% of Workforce
        Nov 22 LXRX Lexicon falls on restructuring program
        Nov 22 LXRX Lexicon to Reposition as Clinical Development-Focused Company Following Regulatory Update From FDA
        Nov 22 LXRX Lexicon to disband sales team, lay off 60% of staff
        Nov 20 LXRX Lexicon Appoints Ivan H. Cheung to Board of Directors
        Nov 18 LXRX Lexicon Pharmaceuticals (NASDAQ:LXRX investor three-year losses grow to 80% as the stock sheds US$107m this past week
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Diabetes Glaucoma Inflammatory Diseases Medicine Psoriasis Rheumatoid Arthritis Alzheimer's Disease Arthritis Autoimmune Disease Biotechnology Buparlisib Cancer Carcinoma Chronic Obstructive Pulmonary Disease Clinical Development Clinical Trial Colitis Disease Drug Discovery
        Biotie Therapies

        Biotie Therapies was a Finnish biotechnology and pharmaceutics company that was acquired by Acorda Therapeutics in January 2016. The company's research and development was focused on drugs for neurodegenerative and psychiatric disorders like Parkinson's disease, Alzheimer's disease and other cognitive disorders, alcohol and drug dependence and post traumatic stress disorder, and inflammatory and fibrotic liver disease. The company's headquarters is in Turku, Western Finland, and it is listed on NASDAQ OMX Helsinki.

        More about Biotie Therapies
        Browse All Tags